Stem cells in pulmonary hypertension: Current understanding and future challenges

Keywords

pulmonary hypertension / stem cells

References

[1] Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43:3618-3731.

[2] Zheng R, Xu T, Wang X, Yang L, Wang J, Huang X. Stem cell therapy in pulmonary hypertension: current practice and future opportunities. Eur Respir Rev. 2023;32:230112.

[3] Sun QW, Sun Z. Stem cell therapy for pulmonary arterial hypertension: an update. J Heart Lung Transplant. 2022;41:692-703.

[4] Oh S, Jung JH, Ahn KJ, et al. Stem cell and exosome therapy in pulmonary hypertension. Korean Circ J. 2022;52:110-122.

[5] Pu X, Du L, Hu Y, et al. Stem/progenitor cells and pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol. 2021;41:167-178.

[6] Ding XF, Liang HY, Yuan B, et al. Efficacy of stem cell therapy for pulmonary arterial hypertension: a systematic review and meta-analysis of preclinical studies. Stem Cell Res Ther. 2019;10:55.

[7] Suen CM, Stewart DJ, Montroy J, et al. Regenerative cell therapy for pulmonary arterial hypertension in animal models: a systematic review. Stem Cell Res Ther. 2019;10:75.

[8] Zakrzewski W, Dobrzynski M, Szymonowicz M, et al. Stem cells: past, present, and future. Stem Cell Res Ther. 2019;10:68.

[9] Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res. 2005;96:442-450.

[10] Loisel F, Provost B, Guihaire J, et al. Autologous endothelial progenitor cell therapy improves right ventricular function in a model of chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg. 2019;157:655-666.e7.

[11] Wang XX, Zhang FR, Shang YP, et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol. 2007;49:1566-1571.

[12] Zhu JH, Wang XX, Zhang FR, et al. Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: open-label pilot study. Pediatr Transplant. 2008;12:650-655.

[13] Granton J, Langleben D, Kutryk MB, et al. Endothelial NO-synthase gene-enhanced progenitor cell therapy for pulmonary arterial hypertension: the PHACeT trial. Circ Res. 2015;117:645-654.

[14] Kanki-Horimoto S, Horimoto H, Mieno S, et al. Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension. Circulation. 2006;114:I181-I185.

[15] Luo L, Chen Q, Yang L, Zhang Z, Xu J, Gou D. MSCs therapy reverse the gut microbiota in hypoxia-induced pulmonary hypertension mice. Front Physiol. 2021;12:712139.

[16] Zhang ZH, Lu Y, Luan Y, et al. Effect of bone marrow mesenchymal stem cells on experimental pulmonary arterial hypertension. Exp Ther Med. 2012;4:839-843.

[17] Huang WC, Ke MW, Cheng CC, et al. Therapeutic benefits of induced pluripotent stem cells in Monocrotaline-induced pulmonary arterial hypertension. PLoS One. 2016;11:e0142476.

RIGHTS & PERMISSIONS

2024 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.